Merck Completes Acquisition of Investigational Bispecific Antibody Therapy from Curon Biopharmaceutical

CN201 is currently being evaluated in Phase I and Phase Ib/II clinical trials for relapsed or refractory non-Hodgkin lymphoma and B-cell acute lymphocytic leukemia.